@article{00afb33ea71b4b238894fd6b2bc6a547,
title = "Relative ellipsoid zone reflectivity and its association with disease severity in age-related macular degeneration: a MACUSTAR study report",
abstract = "Quantification of the relative ellipsoid zone reflectivity (rEZR) might be a structural surrogate parameter for an early disease progression in the context of age-related macular degeneration (AMD). Within the European multicenter, cross-sectional MACUSTAR study, we have devised an automatic approach to determine the mean rEZR [arbitrary units, AU] at two independent visits in SD-OCT volume scans in study participants. Linear mixed-effects models were applied to analyze the association of AMD stage and AMD associated high-risk features including presence of pigmentary abnormalities, reticular pseudodrusen (RPD), volume of the retinal-pigment-epithelial–drusenoid-complex (RPEDC) with the rEZR. Intra-class correlation coefficients (ICC) were determined for rEZR reliability analysis. Within the overall study cohort (301 participants), we could observe decreased rEZR values (coefficient estimate ± standard error) of − 8.05 ± 2.44 AU (p = 0.0011) in the intermediate and of − 22.35 ± 3.28 AU (p < 0.0001) in the late AMD group. RPD presence was significantly associated with the rEZR in iAMD eyes (− 6.49 ± 3.14 AU; p = 0.0403), while there was a good ICC of 0.846 (95% confidence interval: 0.809; 0.876) in the overall study cohort. This study showed an association of rEZR with increasing disease severity and the presence of iAMD high-risk features. Further studies are necessary to evaluate the rEZR{\textquoteright}s value as a novel biomarker for AMD and disease progression.",
author = "{MACUSTAR Consortium} and Marlene Sa{\ss}mannshausen and Charlotte Behning and Ben Isselmann and Matthias Schmid and Finger, {Robert P.} and Holz, {Frank G.} and Steffen Schmitz-Valckenberg and Maximilian Pfau and H. Agostini and L. Altay and R. Atia and F. Bandello and Basile, {P. G.} and C. Behning and M. Belmouhand and M. Berger and A. Binns and Boon, {C. J. F.} and M. B{\"o}ttger and C. Bouchet and Brazier, {J. E.} and T. Butt and C. Carapezzi and J. Carlton and A. Carneiro and A. Charil and R. Coimbra and M. Cozzi and Crabb, {D. P.} and J. Cunha-Vaz and C. Dahlke and {de Sisternes}, L. and H. Dunbar and Finger, {R. P.} and E. Fletcher and H. Floyd and C. Francisco and M. Gutfleisch and R. Hogg and Holz, {F. G.} and Hoyng, {C. B.} and A. Kilani and J. Kr{\"a}tzschmar and L. K{\"u}hlewein and M. Larsen and S. Leal and Lechanteur, {Y. T. E.} and Luhmann, {U. F. O.} and A. L{\"u}ning and I. Marques",
note = "Funding Information: This work was supported by the BONFOR GEROK Program, Faculty of Medicine, University of Bonn, Grant No O-137.0030 to MS and O-137.0026 to ST; by the Anna-Katharina Eichenauer Foundation to MS, by the Maria-von-Linden Program, University of Bonn to ST; by the Dr. Werner Jackst{\"a}dt Nachwuchspreis of the German Retina Society to ST and by the German Research Foundation (DFG, TH 2514/2-1) to ST. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116076. This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA. The sponsors or funding organizations had no role in the design or conduct of the MACUSTAR study (project number: 116076) research. Funding Information: This work was supported by the BONFOR GEROK Program, Faculty of Medicine, University of Bonn, Grant No O-137.0030 to MS and O-137.0026 to ST; by the Anna-Katharina Eichenauer Foundation to MS, by the Maria-von-Linden Program, University of Bonn to ST; by the Dr. Werner Jackst{\"a}dt Nachwuchspreis of the German Retina Society to ST and by the German Research Foundation (DFG, TH 2514/2-1) to ST. This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116076. This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA. The sponsors or funding organizations had no role in the design or conduct of the MACUSTAR study (project number: 116076) research. The communication reflects the authors' views. Neither IMI nor the European Union, and European Federation of Pharmaceutical Industries and Associations (EFPIA), or any associated partners are responsible for any use that may be made of the information contained therein. Publisher Copyright: {\textcopyright} 2022, The Author(s).",
year = "2022",
month = dec,
day = "1",
doi = "https://doi.org/10.1038/s41598-022-18875-5",
language = "English",
volume = "12",
journal = "Scientific reports",
issn = "2045-2322",
publisher = "Springer Nature",
number = "1",
}